Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR001 Combined With Chemotherapy in Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
NCT07235202Phase 2Recruiting
- Start
- Dec 2025
- Primary completion
- Jun 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of MR001 in pancreatic ductal adenocarcinoma (PDAC). Started Dec 2025; status: recruiting.
02
Drugs
MR001
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07235202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07235202.